Search results
Results from the WOW.Com Content Network
This is a list of investigational autism and pervasive developmental disorder drugs, or drugs that are currently under development for clinical use in the treatment of autistic spectrum disorders and/or other pervasive developmental disorders but are not yet approved.
The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse of the drug or other substances may lead to severe psychological or physical dependence. The complete list of Schedule II substances is as follows.
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Vermont, a state with a long waiting list for medically based drug treatment, suspended a doctor’s license over incomplete paperwork. As doctors face scrutiny from the DEA, states have imposed even greater regulations severely limiting access to the medications, according to a 2014 report commissioned by the federal agency SAMHSA.
Its top performer was the lung cancer drug Tagrisso, which had revenues of $5 billion and is a targeted therapy for lung cancer patients with a certain mutation taken as a convenient once-daily pill.
NIDA Notes is a bimonthly newsletter that has been published since 1985. Its scope covers drug abuse research in the areas of treatment and prevention, epidemiology, neuroscience, behavioral science, health services, and AIDS. [16] NIDA-supported studies are also published in other journals. [17]
The skeletal structure of norepinephrine The skeletal structure of dopamine. A norepinephrine–dopamine reuptake inhibitor (NDRI) is a drug used for the treatment of clinical depression, attention deficit hyperactivity disorder (ADHD), narcolepsy, and the management of Parkinson's disease.